Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
From the American Academy of PediatricsStatement of Endorsement

Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants

David M. FleischerPrimary contributors: , David M. FleischerPrimary contributors: , Scott Sicherer, Matthew Greenhawt, Dianne Campbell, Edmond Chan, Antonella Muraro, Susanne Halken, Yitzhak Katz, Motohiro Ebisawa, Lawrence Eichenfield, Hugh Sampson, For the LEAP Study Team, Gideon Lack, George Du Toit, Graham Roberts, Henry Bahnson, Mary Feeney, Jonathan HourihaneSecondary contributors: , Jonathan HourihaneSecondary contributors: , Jonathan Spergel, Michael Young, Amal As’aad, Katrina Allen, Susan Prescott, Sandeep Kapur, Hirohisa Saito, Ioana Agache, Cezmi A. Akdis, Hasan Arshad, Kirsten Beyer, Anthony Dubois, Philippe Eigenmann, Monserrat Fernandez-Rivas, Kate Grimshaw, Karin Hoffman-Sommergruber, Arne Host, Susanne Lau, Liam O’Mahony, Clare Mills, Nikolaus Papadopoulos, Carina Venter, Nancy Agmon-Levin, Aaron Kessel, Richard Antaya, Beth Drolet and Lanny Rosenwasser
Pediatrics September 2015, 136 (3) 600-604; DOI: https://doi.org/10.1542/peds.2015-2394
David M. Fleischer
American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Fleischer
American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Sicherer
American Academy of Pediatrics (AAP)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Greenhawt
American College of Allergy, Asthma & Immunology (ACAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dianne Campbell
Australasian Society of Clinical Immunology and Allergy (ASCIA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edmond Chan
Canadian Society of Allergy and Clinical Immunology (CSACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonella Muraro
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Halken
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yitzhak Katz
Israel Association of Allergy and Clinical Immunology (ISACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Motohiro Ebisawa
Japanese Society for Allergology (JSA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Eichenfield
Society for Pediatric Dermatology (SPD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugh Sampson
World Allergy Organization (WAO)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gideon Lack
World Allergy Organization (WAO)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Du Toit
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Roberts
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Bahnson
Rho Federal Systems Division, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Feeney
World Allergy Organization (WAO)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Hourihane
American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Hourihane
American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Spergel
American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Young
American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amal As’aad
American College of Allergy, Asthma & Immunology (ACAAI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrina Allen
Australasian Society of Clinical Immunology and Allergy (ASCIA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Prescott
Australasian Society of Clinical Immunology and Allergy (ASCIA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandeep Kapur
Canadian Society of Allergy and Clinical Immunology (CSACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirohisa Saito
Japanese Society for Allergology (JSA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioana Agache
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cezmi A. Akdis
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hasan Arshad
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten Beyer
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Dubois
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Eigenmann
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monserrat Fernandez-Rivas
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Grimshaw
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Hoffman-Sommergruber
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arne Host
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Lau
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liam O’Mahony
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clare Mills
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaus Papadopoulos
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carina Venter
European Academy of Allergy and Clinical Immunology (EAACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Agmon-Levin
Israel Association of Allergy and Clinical Immunology (ISACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron Kessel
Israel Association of Allergy and Clinical Immunology (ISACI)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Antaya
Society for Pediatric Dermatology (SPD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beth Drolet
Society for Pediatric Dermatology (SPD)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lanny Rosenwasser
World Allergy Organization (WAO)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF
  • allergy prevention
  • complementary feeding
  • peanut allergy
  • Abbreviations:
    EAACI —
    European Academy of Allergy and Clinical Immunology
    LEAP —
    Learning Early About Peanut Allergy
    NIAID —
    National Institute of Allergy and Infectious Diseases
    NNT —
    Number needed to treat
    SPT —
    Skin prick test
  • In June 2015, the American Academy of Pediatrics endorses and accepts as its policy, the “Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-Risk Infants.” More formal guidelines regarding early-life, complementary feeding practices, and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored Working Group and the European Academy of Allergy and Clinical Immunology (EAACI), and thus, this document should be considered as interim guidance. The publication follows this endorsement and is available at: http://www.jacionline.org/article/S0091-6749%2815%2900785-X/full

    All statements of endorsement from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

    The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food introduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, Australasian Society of Clinical Immunology and Allergy, Canadian Society of Allergy and Clinical Immunology, European Academy of Allergy and Clinical Immunology, Israel Association of Allergy and Clinical Immunology, Japanese Society for Allergology, Society for Pediatric Dermatology, and World Allergy Organization. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases-sponsored Working Group and the European Academy of Allergy and Clinical Immunology.

    Introduction And Rationale

    Peanut allergy is an increasingly troubling global health problem affecting between 1% and 3% of children in many westernized countries. Although multiple methods of measurement have been used and specific estimates differ, there appears to have been a sudden increase in the number of cases in the past 10- to 15-year period, suggesting that the prevalence might have tripled in some countries, such as the United States. Extrapolating the currently estimated prevalence, this translates to nearly 100 000 new cases annually (in the United States and United Kingdom), affecting some 1 in 50 primary school-aged children in the United States, Canada, the United Kingdom, and Australia. A similar increase in incidence is now being noted in developing countries, such as Ghana.1–6

    The purpose of this brief communication is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early rather than delayed peanut introduction during the period of complementary food introduction in infants. A recent study entitled ‘‘Randomized trial of peanut consumption in infants at risk for peanut allergy’’ demonstrated a successful 11% to 25% absolute reduction in the risk of peanut allergy in high-risk infants (and a relative risk reduction of up to 80%) if peanut was introduced between 4 and 11 months of age.7 In light of the significance of these findings, this document serves to better inform the decision-making process for health care providers regarding such potential benefits of early peanut introduction. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases (NIAID)–sponsored Working Group and the European Academy of Allergy and Clinical Immunology (EAACI), and thus this document should be considered interim guidance.

    Summary Of New Evidence

    In the Learning Early About Peanut Allergy (LEAP) trial, 640 high-risk United Kingdom infants (see Box 1) between the ages of 4 and 11 months were randomized to consume peanut products at least 3 times a week (6 g of peanut protein, which is equivalent to 24 g peanuts or 3 teaspoons of peanut butter per week) or to completely avoid peanut products for the first 5 years of life. This included 542 infants found to have negative skin prick test (SPT) responses to peanut at study entry and 98 infants with SPT wheal diameters to peanut of between 1 and 4 mm (minimally positive SPT response) at study entry. An additional 76 children were excluded from study entry before randomization based on a SPT response of greater than 5 mm, which was assumed to result in a very high likelihood of reacting to a peanut challenge. In an intention-to-treat analysis 17.2% in the peanut avoidance group compared with 3.2% in the peanut consumption group had food challenge–proved peanut allergy by age 5 years, corresponding to a 14% absolute risk reduction, a number needed to treat (NNT; eg, the number of persons needed to be treated for one to receive benefit) of 7.1, and a relative risk reduction of 80%.7 When examined in further detail, the isolated beneficial effects for both the primary and secondary prevention of peanut allergy translated to an NNT of 8.5 among the infants with negative SPT responses and an NNT of 4 among the infants with minimally positive SPT responses. Secondary analyses also showed similar levels of prevention in white, black, and Asian (Indian and Pakistani) children. Overall, the risk of early introduction in this group was low: 7 of the 319 children randomized to the consumption group reacted to peanut at the baseline food challenge, suggesting that peanut food challenges and introduction, even in infants with minimally positive SPT responses, are safe and feasible. Six children in the consumption group had peanut allergy during the study, indicating that peanut allergy can still develop despite attempts at primary and secondary prevention. Finally, the LEAP trial only included high-risk infants with a minimal or negative SPT response to peanut and therefore does not address a strategy for those without these risk factors for peanut allergy.7

    Box 1. Enrollment criteria used in the LEAP trial

    Infants considered at ‘‘high risk’’ as defined by the LEAP study criteria:

    Egg allergy: Children with either:

    1. A SPT wheal diameter >6 mm from exposure to raw hen’s egg white and no history of previous egg tolerance

    OR

    2. A SPT wheal diameter >3 mm from exposure to pasteurized hen’s egg white and allergic symptoms related to exposure to hen’s egg

    Severe eczema: An eczematous rash that:

    1. Requires application of topical creams, ointments, or both containing corticosteroids or calcineurin inhibitors and that, if the participant is <6 months of age, lasted for at least 12 of 30 days on 2 occasions or, if the participant is >6 months of age, lasted for at least 12 of 30 days on 2 occasions in the last 6 months

    OR

    2. Is currently or was previously graded >40 by using the modified SCORAD evaluation

    Example of SPT method used in the LEAP trial

     • SPTs to peanut extract should be performed in the presence of a negative control and a positive histamine control.

     • SPTs should be performed in duplicate, and the maximum wheal diameter of the 2 SPT responses should be calculated and rounded up to the greatest whole millimeter. Of note, in the LEAP trial measurement of IgE to peanut resulted in considerably higher rates of sensitization compared with skin testing, which could lead to numerous unnecessary oral peanut challenges.

    How Does The Leap Trial Affect Present Guidance For Early Complementary Feeding Practices?

    Existing guidelines pertaining to the early introduction of complementary foods have indicated that the introduction of highly allergenic foods, such as peanut, need not be delayed past 4 or 6 months of life. However, they do not actively recommend introduction of peanut between 4 and 6 months of age in high-risk infants, and some of these guidelines specify that certain infants considered at high risk for allergic disease are recommended to first consult an expert.8–14 The LEAP data provide Level 1 evidence that the practice of early peanut introduction is safe and effective in selected high risk infants. This study is the first prospective randomized trial of early peanut intervention and informs provider decision making regarding high-risk infants, including those already having a positive peanut SPT response but not yet clinically reactive, to receive the benefits noted in the LEAP trial, which might reduce the risk of peanut allergy up to 80%. Of note, because children with lesser risk factors for peanut allergy were excluded from enrollment in the LEAP trial, there are no prospective randomized data investigating the benefit or risk of early peanut introduction in the general to low-risk populations. Consequently, this communication’s guidance is limited to applying the findings of the LEAP trial to other similar children at high risk in more diverse settings around the world. However, multiple guidelines have not recommended delaying allergen introduction in the general to low-risk populations.

    Interim Guidance Regarding Early Peanut Introduction

    Based on data generated in the LEAP trial and existing guidelines, the following interim guidance is suggested to assist the clinical decision making of health care providers:

    • There is now scientific evidence (Level 1 evidence from a randomized controlled trial) that health care providers should recommend introducing peanut-containing products into the diets of ‘‘high-risk’’ infants early on in life (between 4 and 11 months of age) in countries where peanut allergy is prevalent because delaying the introduction of peanut can be associated with an increased risk of peanut allergy.

    • Infants with early-onset atopic disease, such as severe eczema, or egg allergy in the first 4 to 6 months of life (see Box 1 for example LEAP criteria) might benefit from evaluation by an allergist or physician trained in management of allergic diseases in this age group to diagnose any food allergy and assist in implementing these suggestions regarding the appropriateness of early peanut introduction. Evaluation of such patients might consist of performing peanut skin testing, in-office observed peanut ingestion, or both, as deemed appropriate after discussion with the family. The clinician can perform an observed peanut challenge for those with evidence of a positive peanut skin test response to determine whether they are clinically reactive before initiating at-home peanut introduction. Both strategies were used in the LEAP study protocol.

    • Adherence in the LEAP trial was excellent (92%), with infants randomized to consume peanut ingesting a median of 7.7 g of peanut protein (interquartile range, 6.7-8.8 g) per week during the first 2 years of the trial compared with a median of 0 g in the avoidance group (see Box 2 for examples of peanut-containing foods used in the LEAP trial). Although the outcome of the LEAP regimen was excellent, the study does not address use of alternative doses of peanut protein, minimal length of treatment necessary to induce the tolerogenic effect, or potential risks of premature discontinuation or sporadic feeding of peanut.

    Box 2. Examples of peanut-containing foods used in the LEAP trial

     • Smooth peanut butter (1 teaspoon) mixed with milk or with mashed or pureed fruit

     • Bamba snack* (Osem; approximately two thirds of a 1-oz (25 g) bag; 21 sticks of Bamba)

      — For young infants (<7 months), softened with 20 to 30 mL water or milk and mixed with milk or with mashed or pureed fruit or vegetables

     • Peanut soup

     • Finely ground peanuts mixed into other foods, such as yogurt

    *Other foods more customary to particular nations/cultures can be substituted.

    Whole peanut is not recommended for introduction because this is a choking hazard in children less than 4 years of age.

    Rationale For Evaluating And Applying This Policy To A High-Risk Population

    The LEAP trial demonstrates that early peanut introduction can be successfully carried out in a high-risk population, such as the population defined in the LEAP trial. However, without intervention by health care providers, there is the potential that such high-risk infants will remain at risk for delayed introduction of solids and allergenic foods into their diet because of the widespread belief that such foods can exacerbate eczema.

    There will be more extensive guidelines in the near future from the NIAID Working Group and EAACI Guidelines Group and their multidisciplinary stakeholders. These groups will consider all the available data and determine whether there is sufficient evidence to apply prevention strategies to the general population. However, engagement of the primary care, allergy, and dermatology communities to rapidly implement these findings and change the culture of early feeding practices is essential, and the forthcoming NIAID Working Group’s and EAACI Guidelines Group’s documents will better clarify a best-practices approach.

    Footnotes

      • Received June 2, 2015.
      • Revision received June 3, 2015.
      • Accepted June 3, 2015.
    • Corresponding author: David M. Fleischer, MD, Children’s Hospital Colorado, 13123 E 16th Ave, B518, Aurora, CO 80045. E-mail: david.fleischer{at}childrenscolorado.org.
    • Published on behalf of the American Academy of Allergy, Asthma & Immunology; American Academy of Pediatrics; American College of Allergy, Asthma & Immunology; Australasian Society of Clinical Immunology and Allergy; Canadian Society of Allergy and Clinical Immunology; European Academy of Allergy and Clinical Immunology; Israel Association of Allergy and Clinical Immunology; Japanese Society for Allergology; Society for Pediatric Dermatology; and World Allergy Organization. Copublished in the Journal of Allergy and Clinical Immunology; Pediatrics; Annals of Allergy, Asthma, & Clinical Immunology; Allergy; Allergy, Asthma, & Clinical Immunology; World Allergy Organization Journal; Journal of Paediatrics and Child Health; and Pediatric Dermatology.

    • 0091-6749/$36.00

    • http://dx.doi.org/10.1016/j.jaci.2015.06.001

    References

    1. 1.↵
      1. Nwaru BI,
      2. Hickstein L,
      3. Panesar SS,
      4. Muraro A,
      5. Werfel T,
      6. Cardona V,
      7. et al
      . The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy 2014;69:62–75.
      OpenUrlCrossRefPubMed
    2. 2.
      1. Osborne NJ,
      2. Koplin JJ,
      3. Martin PE,
      4. Gurrin LC,
      5. Lowe AJ,
      6. Matheson MC,
      7. et al
      . Prevalence of challenge-proven IgE-mediated food allergy using populationbased sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011;127:668–76.
      OpenUrlCrossRef
    3. 3.
      1. Venter C,
      2. Hasan Arshad S,
      3. Grundy J,
      4. Pereira B,
      5. Bernie Clayton C,
      6. Voigt K,
      7. et al
      . Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy 2010;65:103–8.
      OpenUrlCrossRefPubMed
    4. 4.
      1. Sicherer SH,
      2. Mu∼noz-Furlong A,
      3. Godbold JH,
      4. Sampson HA
      . US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010;125:1322–6.
      OpenUrlCrossRefPubMed
    5. 5.
      1. Soller L,
      2. Ben-Shoshan M,
      3. Harrington DW,
      4. Fragapane J,
      5. Joseph L,
      6. St Pierre Y,
      7. et al
      . Overall prevalence of self-reported food allergy in Canada. J Allergy Clin Immunol 2012;130:986–8.
      OpenUrlCrossRefPubMed
    6. 6.↵
      1. Amoah AS,
      2. Obeng BB,
      3. Larbi IA,
      4. Versteeg SA,
      5. Aryeetey Y,
      6. Akkerdass JH,
      7. et al
      . Peanut-specific IgE antibodies in asymptomatic Ghanaian children possibly caused by carbohydrate determinant cross-reactivity. J Allergy Clin Immunol 2013;132:639–47.
      OpenUrlCrossRef
    7. 7.↵
      1. Du Toit G,
      2. Roberts G,
      3. Sayre PH,
      4. Bahnson HT,
      5. Radulovic S,
      6. Santos AF,
      7. et al
      . Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015;372:803–13.
      OpenUrlCrossRefPubMed
    8. 8.↵
      1. Greer FR,
      2. Sicherer SH,
      3. Burks AW
      . Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008;121:183–91.
      OpenUrlAbstract/FREE Full Text
    9. 9.
      1. Muraro A,
      2. Halken S,
      3. Arshad SH,
      4. Beyer K,
      5. Dubois AE,
      6. Du Toit G,
      7. et al
      . EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy 2014;69:590–601.
      OpenUrlCrossRefPubMed
    10. 10.
      1. de Silva D,
      2. Geromi M,
      3. Halken S,
      4. Host A,
      5. Panesar SS,
      6. Muraro A,
      7. et al
      . Primary prevention of food allergy in children and adults: systematic review. Allergy 2014;69:581–9.
      OpenUrlCrossRefPubMed
    11. 11.
      1. Fleischer DM,
      2. Spergel JM,
      3. Assa’ad AH,
      4. Pongracic JA
      . Primary prevention of allergic disease through nutritional interventions. J Allergy Clin Immunol Pract 2013;1:29–36.
      OpenUrlCrossRefPubMed
    12. 12.
      1. Chan ES,
      2. Cummings C
      . Canadian Paediatric Society, Community Paediatrics Committee and Allergy Section. Dietary exposures and allergy prevention in high-risk infants: A joint statement with the Canadian Society of Allergy and Clinical Immunology. Paediatr Child Health 2013;18:545–54.
      OpenUrl
    13. 13.
      1. Agostoni C,
      2. Decsi T,
      3. Fewtrell M,
      4. Goulet O,
      5. Kolacek S,
      6. Koletzko B,
      7. et al
      . Complementary feeding: a commentary by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2008;46(1):99–110.
      OpenUrlCrossRefPubMed
    14. 14.↵
      Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA infant feeding advice. Available at: http://www.allergy.org.au/images/stories/aer/infobulletins/2010pdf/ASCIA_Infant_Feeding_Advice_2010.pdf. Accessed April 2, 2015.
    • © 2015 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. All rights reserved.
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 136, Issue 3
    1 Sep 2015
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants
    David M. FleischerPrimary contributors: , David M. FleischerPrimary contributors: , Scott Sicherer, Matthew Greenhawt, Dianne Campbell, Edmond Chan, Antonella Muraro, Susanne Halken, Yitzhak Katz, Motohiro Ebisawa, Lawrence Eichenfield, Hugh Sampson, For the LEAP Study Team, Gideon Lack, George Du Toit, Graham Roberts, Henry Bahnson, Mary Feeney, Jonathan HourihaneSecondary contributors: , Jonathan HourihaneSecondary contributors: , Jonathan Spergel, Michael Young, Amal As’aad, Katrina Allen, Susan Prescott, Sandeep Kapur, Hirohisa Saito, Ioana Agache, Cezmi A. Akdis, Hasan Arshad, Kirsten Beyer, Anthony Dubois, Philippe Eigenmann, Monserrat Fernandez-Rivas, Kate Grimshaw, Karin Hoffman-Sommergruber, Arne Host, Susanne Lau, Liam O’Mahony, Clare Mills, Nikolaus Papadopoulos, Carina Venter, Nancy Agmon-Levin, Aaron Kessel, Richard Antaya, Beth Drolet, Lanny Rosenwasser
    Pediatrics Sep 2015, 136 (3) 600-604; DOI: 10.1542/peds.2015-2394

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants
    David M. FleischerPrimary contributors: , David M. FleischerPrimary contributors: , Scott Sicherer, Matthew Greenhawt, Dianne Campbell, Edmond Chan, Antonella Muraro, Susanne Halken, Yitzhak Katz, Motohiro Ebisawa, Lawrence Eichenfield, Hugh Sampson, For the LEAP Study Team, Gideon Lack, George Du Toit, Graham Roberts, Henry Bahnson, Mary Feeney, Jonathan HourihaneSecondary contributors: , Jonathan HourihaneSecondary contributors: , Jonathan Spergel, Michael Young, Amal As’aad, Katrina Allen, Susan Prescott, Sandeep Kapur, Hirohisa Saito, Ioana Agache, Cezmi A. Akdis, Hasan Arshad, Kirsten Beyer, Anthony Dubois, Philippe Eigenmann, Monserrat Fernandez-Rivas, Kate Grimshaw, Karin Hoffman-Sommergruber, Arne Host, Susanne Lau, Liam O’Mahony, Clare Mills, Nikolaus Papadopoulos, Carina Venter, Nancy Agmon-Levin, Aaron Kessel, Richard Antaya, Beth Drolet, Lanny Rosenwasser
    Pediatrics Sep 2015, 136 (3) 600-604; DOI: 10.1542/peds.2015-2394
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Introduction And Rationale
      • Summary Of New Evidence
      • How Does The Leap Trial Affect Present Guidance For Early Complementary Feeding Practices?
      • Interim Guidance Regarding Early Peanut Introduction
      • Rationale For Evaluating And Applying This Policy To A High-Risk Population
      • Footnotes
      • References
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • Recent Developments in Atopic Dermatitis
    • Google Scholar

    More in this TOC Section

    • Ethical Considerations in Pediatricians’ Use of Social Media
    • 2021 Recommendations for Preventive Pediatric Health Care
    • Recommended Childhood and Adolescent Immunization Schedule: United States, 2021
    Show more From the American Academy of Pediatrics

    Similar Articles

    Subjects

    • AAP Policy Collections by Authoring Entities
      • Endorsed Documents
    • Current Policy
    • Allergy/Immunology
      • Allergy/Immunology

    Keywords

    • allergy prevention
    • complementary feeding
    • peanut allergy
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics